NovoCure
NVCR
237 hedge funds and large institutions have $1.4B invested in NovoCure in 2024 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 81 increasing their positions, 63 reducing their positions, and 25 closing their positions.
132% more call options, than puts
Call options by funds: $29.2M | Put options by funds: $12.6M
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
29% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 63
8% more funds holding
Funds holding: 219 → 237 (+18)
2% more capital invested
Capital invested by funds: $1.37B → $1.4B (+$27.8M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.68% less ownership
Funds ownership: 86.03% → 83.35% (-2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$8.48M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.21M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.81M |
| 4 |
Man Group
London,
United Kingdom
|
+$5.68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$41.9M |
| 2 |
Morgan Stanley
New York
|
-$15.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$14.5M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$14.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.36M |
NVCR Hedge Fund Activity: Q1 2024 in Review
237 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2024, worth a combined $1.4B — up 2% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new NVCR positions and 25 closed out — a net gain of 19 holders — while 81 added to existing stakes and 63 trimmed.
The largest buyer was Bank of America, adding an estimated $8.48M. The largest seller was Baillie Gifford & Co, cutting an estimated $41.9M.
- 237 institutional investors held NovoCure (NVCR) as of Q1 2024, up from 219 in Q4 2023.
- Funds reported $1.4B of NovoCure stock for Q1 2024, up 2% quarter-over-quarter.
- 44 funds opened new NovoCure positions in Q1 2024 and 25 closed out, a net change of +19 holders.
- The largest NovoCure buyer in Q1 2024 was Bank of America, an estimated $8.48M added.
- The largest NovoCure seller in Q1 2024 was Baillie Gifford & Co, an estimated $41.9M sold.
Based on aggregated 13F filings for Q1 2024.